Arthur Ryan Net Worth

The estimated Net Worth of Arthur F Ryan is at least $32.2 Milhão dollars as of 3 September 2024. Mr. Ryan owns over 100 units of Regeneron Pharmaceuticals stock worth over $20,183,119 and over the last 21 years he sold REGN stock worth over $11,314,284. In addition, he makes $724,993 as Independent Director at Regeneron Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Ryan REGN stock SEC Form 4 insiders trading

Arthur has made over 62 trades of the Regeneron Pharmaceuticals stock since 2010, according to the Form 4 filled with the SEC. Most recently he sold 100 units of REGN stock worth $117,869 on 3 September 2024.

The largest trade he's ever made was exercising 115,000 units of Regeneron Pharmaceuticals stock on 14 September 2011 worth over $2,084,950. On average, Arthur trades about 3,748 units every 56 days since 2004. As of 3 September 2024 he still owns at least 17,682 units of Regeneron Pharmaceuticals stock.

You can see the complete history of Mr. Ryan stock trades at the bottom of the page.

Arthur Ryan biography

Arthur F. Ryan serves as Independent Director of the Company. In 2008, Mr. Ryan retired as the Chairman of the Board of Prudential Financial, Inc., one of the largest diversified financial institutions in the world. He served as Chief Executive Officer of Prudential until 2007. Prior to joining Prudential in 1994, Mr. Ryan served as President and Chief Operating Officer of Chase Manhattan Bank since 1990. Mr. Ryan managed Chase’s worldwide retail bank between 1984 and 1990. From 2008 to 2013, Mr. Ryan served as a non-executive director of the Royal Bank of Scotland Group plc. From 2009 to 2019, Mr. Ryan served as a director of Citizens Financial Group, Inc., a retail bank holding company that became publicly traded in 2014, and also served as its lead director, chair of the Compensation and Human Resources Committee, and a member of the Nominating and Corporate Governance Committee. Mr. Ryan’s substantial leadership experience as a chief executive officer of leading companies in the banking and insurance industries, and his extensive business experience and financial expertise, led the board to conclude that Mr. Ryan should serve as a director.

What is the salary of Arthur Ryan?

As the Independent Director of Regeneron Pharmaceuticals, the total compensation of Arthur Ryan at Regeneron Pharmaceuticals is $724,993. There are 15 executives at Regeneron Pharmaceuticals getting paid more, with P. Roy Vagelos having the highest compensation of $22,304,300.

How old is Arthur Ryan?

Arthur Ryan is 77, he's been the Independent Director of Regeneron Pharmaceuticals since 2003. There are 1 older and 23 younger executives at Regeneron Pharmaceuticals. The oldest executive at Regeneron Pharmaceuticals, Inc. is P. Roy Vagelos, 90, who is the Chairman of the Board, Director.

Insiders trading at Regeneron Pharmaceuticals

Over the last 22 years, insiders at Regeneron Pharmaceuticals have traded over $13,084,686,326 worth of Regeneron Pharmaceuticals stock and bought 8,562,481 units worth $2,539,854,760 . The most active insiders traders include Sanofi, Pharma Ag Novartis, eLeonard S Schleifer. On average, Regeneron Pharmaceuticals executives and independent directors trade stock every 8 days with the average trade being worth of $47,694,347. The most recent stock trade was executed by Marion Mc Court on 3 September 2024, trading 1,000 units of REGN stock currently worth $381,400.

What does Regeneron Pharmaceuticals do?

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.

Complete history of Mr. Ryan stock trades at Regeneron Pharmaceuticals e Citizens Inc

Regeneron Pharmaceuticals executives and stock owners

Regeneron Pharmaceuticals executives and other stock owners filed with the SEC include:

• P. Roy Vagelos,
  Chairman of the Board, Director
• Leonard Schleifer,
  President, Chief Executive Officer, Director
• George Yancopoulos,
  President, Chief Scientific Officer, Director
• Marion McCourt,
  Senior Vice President - Commercial
• Andrew Murphy,
  Executive Vice President - Research
• Neil Stahl,
  Executive Vice President - Research and Development
• Robert Landry,
  Chief Financial Officer, Executive Vice President - Finance
• Daniel Van Plew,
  Executive Vice President, General Manager - Industrial Operations and Product Supply
• Dr. George D. Yancopoulos M.D., Ph.D.,
  Scientific Founder, Pres, Chief Scientific Officer & Director
• Dr. Leonard S. Schleifer M.D., Ph.D.,
  Founder, Pres, CEO & Director
• Dr. George D. Yancopoulos,
  Scientific Founder, Pres, Chief Scientific Officer & Director
• Robert E. Landry Jr.,
  Exec. VP of Fin. & CFO
• Daniel P. Van Plew,
  Exec. VP and GM of Industrial Operations & Product Supply
• Joseph J. LaRosa,
  Exec. VP, Gen. Counsel & Sec.
• Dr. Andrew J. Murphy,
  Exec. VP of Research
• Arthur Ryan,
  Independent Director
• George Sing,
  Independent Director
• Christine Poon,
  Independent Director
• Michael Brown,
  Independent Director
• Huda Zoghbi,
  Independent Director
• Joseph Goldstein,
  Independent Director
• Bonnie Bassler,
  Independent Director
• N. Anthony Coles,
  Independent Director
• Marc Tessier-Lavigne,
  Independent Director
• Christopher Fenimore,
  Vice President, Controller
• Joseph LaRosa,
  Executive Vice President, General Counsel, Secretary
• Justin Holko,
  VP of Investor Relations
• Bob McCowan,
  Sr. VP of IT & Chief Information Officer
• Gerald Underwood,
  Sr. VP of Technical Operations
• Christopher R. Fenimore,
  Sr. VP, Head of Accounting & Controller
• Patrice Gilooly,
  Sr. VP of Quality Assurance & Operations
• Charles A Baker,
  Director
• Michael S Aberman,
  SVP Strategy Investor Relation
• Sanofi,
  
• Robert J Terifay,
  EVP Commercial
• Alfred G Gilman,
  Director
• Robert Alexander Ingram,
  Director
• Eric M Shooter,
  Director
• Murray A Goldberg,
  SVP Administration & Asst Secr
• Stuart Kolinski,
  SVP General Counsel and Secret
• Amerique Du Nord S.N.C. San...,
  
• Peter Dworkin,
  VP Investor Relations & Commun
• Randall Rupp,
  SVP, Manufuring Operations
• Pharma Ag Novartis,
  10% owner
• Hans Peter Guler,
  VP Clinical Programs
• William Roberts,
  VP Reg Dev & Med Safety
• Peter Powchik,
  SVP Clinical Development & Reg
• Douglas S Mc Corkle,
  VP Controller and Asst Treasur
• Craig B. Thompson,
  Director
• Kathryn Guarini,
  Director
• David P Schenkein,
  Director
• Jason Pitofsky,
  VP Controller